跳至主要内容
临床试验/NCT00105456
NCT00105456已完成不适用

registHER: An Observational Cohort Study of Patients With HER2 Positive Metastatic Breast Cancer

Genentech, Inc.0 个研究点目标入组 1,000 人开始时间: 2003年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,000

研究概览

简要总结

This is a prospective observational cohort study designed to describe effectiveness and safety (treatment outcomes and clinically significant cardiac adverse events, respectively) in patients with HER2-positive metastatic breast cancer.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Signed Informed Consent document (unless the IRB has granted a waiver of consent)
  • Signed Authorization for the Use and Disclosure of Health Information document
  • HER2-positive breast cancer
  • Initial diagnosis of metastatic (Stage IV) breast cancer within 6 months prior to enrollment
  • Availability of cancer-specific historical data points in the patient's medical records

排除标准

  • There are no exclusion criteria for participation in this trial

研究者

申办方类型
Industry

相似试验

A Study of Patients With HER2-Positive Metastatic... | 临床试验